The Federal Government on Wednesday evening confirmed the receipt of a usual HIV prevention injection familiar as Lenacapavir.
The development, approved by the Coordinating Minister of Health and Social Welfare, Ali Pate, and supported across the International Finance, represents a primary advancement in the country’s HIV prevention efforts and supplementary strengthens Nigeria’s commitment to expanding groundbreaking HIV prevention options.
The introduction of Lenacapavir for pre-exposure prophylaxis marks a large action toward broadening the selection of prevention choices equipped to individuals at exposure of HIV infection.
As a extended-acting injectable option, LEN PrEP has the prospective to enhance adherence and continue entry to productive HIV prevention services for populations that may encounter challenges together with daily oral prevention options.
Announcing the arrival in a observation, the Statewide Mediator of the Statewide HIV, Viral Hepatitis and STDs Management Programme at the Federal Ministry of Health and Social Welfare, Dr Adebobola Bashorun, said the Federal Government’s receipt of LEN PrEP reflects Nigeria’s continued dedication to leveraging innovation and evidence-based interventions to accelerate shift forward toward epidemic management.
By expanding prevention options and strengthening solution delivery, he said the country was taking decisive steps to reduced recent HIV infections and strengthen health outcomes for communities across Nigeria.
Bashorun said, “NASCP, in organization together with partners and stakeholders, will labor to confirm the low-exposure introduction, strategic deployment, and economical integration of Lenacapavir into the domestic HIV prevention options. The arrival of prolonged-acting injectable Lenacapavir is a transparent demonstration of Nigeria’s tackle to scale up novel solutions and upgrade the fight against HIV.
“Together, Nigeria moves closer to ending HIV as a society health exposure.”
Lenacapavir is an injectable treatment administered twice yearly, offering a greater convenient selection to daily oral preventive medications.
The drug is expected to be prepared in Nigeria and 119 other low- and middle-earnings countries at an budget-approachable expense of $40 per people annually, following voluntary licensing agreements using generic manufacturers.
The publish Nigeria Receives HIV Prevention Injection appeared opening on Statistics Nigeria.
The rollout will support continuing efforts to increase availability to prevention services during the time that reinforcing Nigeria’s broader HIV reaction.
“NASCP remains committed to advancing equitable entry to HIV prevention, testing, treatment, and care services.
